The relationship between a multi-specific antibody's design and its function is often non-intuitive. LabGenius's ML platform excels by exploring this complex "fitness landscape" without human bias, identifying high-performing molecules that a rational designer would deem too unconventional or "crazy."

Contrary to the popular belief that antibody development is a bespoke craft, modern methods enable a reproducible, systematic engineering process. This allows for predictable creation of antibodies with specific properties, such as matching affinity for human and animal targets, a feat once considered a "flight of fancy."

The core philosophy behind ESMFold is that massive datasets and large transformer models can learn fundamental biological principles without needing built-in domain knowledge, applying Rich Sutton's "The Bitter Lesson" directly to bioinformatics.

As biologics evolve into complex multi-specific and hybrid formats, the number of design parameters (valency, linkers, geometry) becomes too vast for experimental testing. AI and computational design are becoming essential not to replace scientists, but to judiciously sample the enormous design space and guide engineering efforts.

Designing therapeutics with immense combinatorial complexity is impossible through rational design alone. The optimal approach is to first use human biological hypotheses to narrow the vast search space. Then, employ large-scale screening and data analysis to optimize within that constrained space, navigating variables too complex for human comprehension.

Instead of screening billions of nature's existing proteins (a search problem), AI-powered de novo design creates entirely new proteins for specific functions from scratch. This moves the paradigm from hoping to find a match to intentionally engineering the desired molecule.

Trained only on sequence prediction, ESM-C independently developed a hierarchical feature space mirroring decades of human scientific discovery. Its learned representations range from basic biochemical properties to complex, abstract functional concepts, all without prior biological knowledge.

Generate Biomedicines' AI learns the fundamental rules of protein structure and function, much like a language's grammar. This allows it to design entirely new proteins by generating novel "sentences" (sequences) that are biologically coherent and functional, rather than just mimicking existing ones found in nature.

Resvita Bio's approach isn't about creating proteins from scratch. Instead, they use machine learning to 'read the book of life comprehensively,' analyzing how different organisms have evolved to solve the same biological problem. This allows them to synthesize nature's best solutions into an ideal therapeutic protein.